Type of Manuscript: Original Research Article

Psychosocial and Behavioral Responses and SARS-CoV-2 Transmission Prevention Behaviors while Working during the COVID-19 Pandemic

Araliya M. Senerat¹; Zachary Pope^{1,2}; Sarah Rydell³; Aidan Mullan⁴, Veronique Roger^{5,6}; Mark A. Pereira³

¹Well Living Lab, 221 1st Ave SW, Rochester, MN, 55902

²Department of Physiology and Biomedical Engineering, Mayo Clinic, 200 1st St SW, Rochester, MN 55905

³Division of Epidemiology & Community Health, University of Minnesota, 1300 South Second Street, Suite 300, Minneapolis, MN, 55454

⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

⁵Department of Cardiovascular Diseases Medicine, Mayo Clinic College of Medicine, Rochester, MN

⁶Now with Epidemiology and Community Health Branch National Heart, Lung and Blood Institute, National Institutes of Health

Corresponding author: Araliya M. Senerat, Well Living Lab, 221 1st Ave SW, Rochester, MN 55902, 507-550-1139 x664, araliya.senerat@delos.com

Running Title: COVID-19 Psychosocial and Behavioral Responses

Conflicts of Interest: None declared.

Sources of Funding: The results reported herein correspond to specific aims of SDG Rapid Response Grant to investigator Dr. Mark A. Pereira from the University of Minnesota. Dr. Mark A. Pereira is the Principal Investigator of the project, and the Global Programs and Strategy Alliance (GPS Alliance) of the University of Minnesota is the funding agency. This work was also supported by Delos Living, LLC.

Data Accessibility: Our data are available upon specific request to the corresponding author.

Acknowledgements: The authors thank the staff of the Well Living Lab for their support. We acknowledge Qingyang Liu for her helpful guidance with analyzing the data, Laura Kjarland for assistance with survey deployment, and Austin Hoeg for his assistance with the project.

Abstract

Background

The impact of coronavirus disease-2019 (COVID-19) on psychosocial and behavioral responses of the non-healthcare workforce is unknown. This study investigated these outcomes in this population during the pandemic while also evaluating transmission prevention behavior implementation at the workplace.

Methods

We deployed the baseline questionnaire of a prospective online survey from November 2020-February 2021 to U.S.-based employees. The survey included questions on psychosocial and behavioral responses in addition to transmission prevention behaviors (e.g., mask wear). Select questions asked employees to report perceptions and behaviors 'before' and 'during' the COVID-19 pandemic. Data were analyzed descriptively and stratified by work from home (WFH) percentage.

Results

In total, 3,607 employees completed the survey from eight companies. Most participants (70.0%) averaged \geq 90% of their time WFH during the pandemic. Employees reported increases in stress (54.0%), anxiety (57.4%), fatigue (51.6%), and feeling unsafe (50.4%) from before to during the pandemic, while feeling a lack of companionship (60.5%) and isolation from others (69.3%). Productivity was perceived to decrease, and non-work screen time and alcohol consumption to increase, for 43.0%, 50.7%, and 25.1% of employees, respectively, from before to during the pandemic. Adverse changes were worse among those with lower WFH percentages. Most

employees reported wearing a mask (98.2%), washing hands regularly (95.7%), and physically distancing (93.6%) when at workplace.

Conclusion

Results suggested worsened psychosocial and behavioral outcomes from before to during the

COVID-19 pandemic and higher transmission prevention behavior implementation among non-

healthcare employees. Observations provide novel insight into how the COVID-19 pandemic has

impacted non-healthcare employees.

Keywords: COVID-19, Survey, Behavior, Psychosocial Health, Prevention Behaviors, SARS-CoV-2, Public Health, Epidemiology

Introduction

Coronavirus disease-19 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, has resulted in high morbidity and mortality since being declared a global pandemic in March 2020.¹⁻³ As most SARS-CoV-2 infections are transmitted by asymptomatic individuals,⁴ infection control measures have been and continue to be vital even as effective vaccines are administered. Across many workforce sectors, companies have implemented mitigation strategies, including mandates that employees work from home if possible, while also requiring engagement in SARS-CoV-2 transmission prevention behaviors (e.g., physical distancing, mask wear, hand/surface disinfection).⁵⁻⁷ While these mitigation strategies on employees may arise (e.g., feelings of isolation, stress/anxiety, adverse health behavior changes).

The COVID-19 pandemic has led to increased prevalence⁸⁻¹⁴ of higher self-reported stress, anxiety, depression, episodes of acute panic, obsessive behaviors, and post-traumatic stress syndrome (PTSD), among others.¹⁰ Widespread quarantine and fear of self/loved ones getting COVID-19 are among the largest contributors to observed poorer psychosocial health.^{10,11} Mental health problems are also higher among those diagnosed with COVID-19 compared to those not directly affected,¹⁵ as well as among those who quarantine to prevent the spread of COVID-19 and other diseases.¹⁶ Within the workplace, past literature noted that being a healthcare worker or caregiver of persons with SARS-CoV in 2003 was associated with higher likelihood of negative psychosocial outcomes, exacerbating the impact of the COVID-19 pandemic have impacted the psychosocial health of non-healthcare employees has scantly been studied.

The SARS-CoV-2 virus spreads primarily via small airborne infectious particles (i.e., aerosols) that infected individuals may generate when breathing, coughing, sneezing, or talking.¹⁷⁻²⁷ A less common transmission route is via larger respiratory droplets that deposit onto nearby surfaces.^{25,27-52} A recent meta-analysis⁵³ and several standalone investigations⁵⁴⁻⁵⁹ have shown the ability of mask wearing, physical distancing, and hand/surface disinfection to mitigate transmission of various coronaviruses. Thus, SARS-CoV-2 prevention behaviors in the workplace are critical to reduce COVID-19 infection rates, with engagement in these behaviors also associated with lower levels of stress, anxiety, and depression.¹¹

Governmental recommendations are in place for SARS-CoV-2 transmission prevention at the workplace.⁶⁰ Yet, few data exist across non-healthcare employee workforce sectors regarding employee: (1) psychosocial outcomes (e.g., stress, anxiety, safety) and perceptions as it relates to working during the COVID-19 pandemic; (2) behavioral outcomes (e.g., smoking, alcohol consumption, physical activity); and (3) implementation of SARS-CoV-2 transmission prevention behaviors at the workplace. Survey collection of such data would inform workplace strategies to reduce negative psychosocial outcomes among employees as more individuals return regularly to the workplace, while also offering insight on workplace mitigation of COVID-19 and other respiratory illnesses.

The purpose of our study was to examine COVID-19-related psychosocial outcomes, prevention practices, and health behaviors among employees across numerous workforce sectors.

Methods

This study was approved by the University of Minnesota (IRB #: STUDY00010426) and Mayo Clinic (IRB #: 20-007642) Institutional Review Boards. All study participants gave informed consent.

Study Design and Survey Development

We designed a prospective online survey entitled "*Characterizing Awareness of SARS-CoV-2 PrevenTion and Understanding Responses and Experiences (CAPTURE) Survey*", with this survey deployed at baseline, three months, six months, and one year. As the follow-up surveys are still ongoing, only the baseline results are presented here. The CAPTURE Survey consisted of 48 questions across eight sections. These sections included consent/screening, demographics, job description, and general health-related questions as well as sections regarding: (1) the socioeconomic impact of COVID-19; (2) personal SARS-CoV-2 prevention behaviors at the workplace; (3) perceptions of the importance/efficacy of SARS-CoV-2 prevention behaviors; (4) workplace COVID-19 culture and practices; (5) psychosocial experiences and perceptions before and during the COVID-19 pandemic; and (6) health behaviors before and during the COVID-19 pandemic. See 'Measures' and Appendix A for description of survey components/questions. We piloted the CAPTURE Survey twice with experts at the Well Living Lab, Mayo Clinic, and the University of Minnesota over 1.5 months before deployment. The CAPTURE Survey completion time was ~12 minutes.

The CAPTURE Survey was deployed using the Mayo Clinic's Qualtrics Platform. Survey responses were deidentified and given a unique study ID that consisted of a series of numbers that had no meaning to employees' personal identifying characteristics. We used this ID to track each individual employee in the research database.

Inclusion and Exclusion Criteria

7

Company-level inclusion criteria were: (1) any public or private company; and (2) inbusiness at time of baseline survey distribution. We assessed these company-level criteria before contacting each company regarding their employees' potential participation in the CAPTURE Survey. Employee-level inclusion criteria were: (1) \geq 18 years old; (2) English speaking; (3) currently employed by the company; and (4) working \geq 50% of their workweek indoors given that SARS-CoV-2 is most likely to spread indoors. Employees were excluded if they were: (1) <18 years old; (2) unemployed; (3) working primarily outdoors; and (4) did not work within the U.S. We excluded employees working outside the U.S. given the differing cultures, practices, and severity of the COVID-19 pandemic between the U.S. and other countries.

<u>Measures</u>

Consent/Screening, Demographics, Job Descriptions, and General Health

We gathered each employee's age, employment status, employer (i.e., company), and U.S. location. Average percentage of workweek time working indoors was assessed on a sliding 0-100% scale in 1%-increments. Demographic information, job descriptions, and general health-related information were queried using questions adapted from the *Stand and Move at Work* (SMW) group randomized trial and the Coronary Artery Risk Development in Young Adults (CARDIA) study.^{61,62}

Socioeconomic Impact of COVID-19

We developed questions assessing the average number of hours/week that the employee worked in total and face-to-face at the workplace. We assessed average percentage of workweek hours spent working from home (WFH) on a sliding 0-100% scale in 1%-increments, with this question asked in parallel to acquire 'before' and 'during' COVID-19 WFH percentages. We also adapted questions from the SMW trial and the Environmental Influences on Child Health

Outcomes (ECHO) study to examine health insurance coverage and doctors visits differed before and during COVID-19.^{62,63}

Psychosocial Outcomes and Perceptions

We assessed employee's frequency of feeling stressed, anxious, fatigued, and unsafe before and during COVID-19 on a 5-point Likert-type scale (1: *Never*; 5: *All the time*), while also using a 5-point Likert-type scale (1: *Low*; 5: *High*) to assess employees' perceived productivity before and during COVID-19. These questions were adapted from the SMW trial.⁶² We developed questions to evaluate whether employees felt threatened or afraid of COVID-19, as well as their fear of catching the disease when around other people, assessed on a 5-point Likert-type scale (1: *Strongly Disagree*; 5: *Strongly Agree*). We adapted questions from the SMW trial to assess employee engagement in health behaviors before and during COVID-19. These health behaviors included physical activity, non-work-related screen time, sleep, and alcohol consumption.

SARS-CoV-2 Prevention Behaviors at the Workplace

We included questions that asked about frequency of: (1) SARS-CoV-2 prevention behaviors (mask wear, glove wear, handwashing, physical distancing, surface disinfection) that an employee and their coworkers have taken when at the workplace; and (2) company provision of SARS-CoV-2 prevention supplies. These questions were asked on a 5-point Likert-type scale (1: *Never*; 5: *Always*). We also assessed what types of SARS-CoV-2 prevention behavior training had been provided by employees' companies and whether the employee perceived SARS-CoV-2 prevention behaviors to be effective at preventing the spread of COVID-19, the latter on a 4point Likert-type scale (1: *Not Important*; 4: *Very Important*). Importantly, these questions had

"not applicable" and/or "prefer not to answer" options given the sensitivity of these questions and the larger social discussion around COVID-19 in the U.S.

COVID-19 Symptomology and Diagnosis

We inquired whether the employee had experienced any COVID-19 symptoms and/or been diagnosed with COVID-19 using questions adapted from ECHO, Epidemic-Pandemic Impacts Inventory, CARDIA, Three-Item Loneliness Scale, and Coronavirus Questionnaire.⁶¹⁻⁶⁶

<u>Recruitment & Survey Deployment</u>

We contacted a convenience sample of 234 U.S. companies regarding CAPTURE Survey participation through word of mouth, emails, LinkedIn messages, and website form submissions. Figure 1 reviews the number of companies contacted and interested as well as the number of participating companies. We spoke with human resource personnel, managers, and/or supervisors (hereafter, key contacts) within companies returning correspondence. A short, informational presentation was provided to key contacts of interested companies that outlined the CAPTURE Survey's aims, company and employee participation requirements, and the potential benefits of the company's participation. Companies were given two CAPTURE Survey deployment choices if they agreed to have employees participate: (1) company sent out a company-wide email with CAPTURE Survey link and informational materials that invited employee participation; or (2) company collected email addresses of interested employees and shared those email addresses with us after which we deployed the CAPTURE Survey link to those email addresses only. Four companies chose to generate their own company-wide deployment email, and we sent out company-provided emails to four companies. While employees from participating companies were strongly encouraged to participate, they were told participation was completely voluntary and had no effect on their company employment or

relationship with us. The CAPTURE Survey was sent to employees of participating companies starting November 20, 2020, and the baseline survey closed February 8, 2021. A reminder email was sent approximately 5-7 business days after initial deployment with each company, with the survey open to employees for up to three weeks after the initial deployment date.

Statistical Analyses

CAPTURE Survey responses were downloaded from Mayo Clinic's Qualtrics Platform. Data were cleaned using Microsoft Excel and uploaded to Python 3.9 for further cleaning and analyses using Jupyter Notebook for Windows 1.3.1093. Duplicates were examined by the date of first survey completion and CAPTURE Survey progress completion for each duplicate entry. Of the duplicates, we kept the CAPTURE Survey entry with the highest progress completion as long as survey completion fell within a 3-week time period allocated for employees of a given company to complete the survey.

In addition to determining prevalence and mean responses for the entire cohort, we also stratified by WFH categories: $\leq 25\%$, 26-50%; 51-75%; >75%. Further, we compared employee responses to questions asking about psychosocial experiences, perceptions, and health behaviors 'before' and 'during' the COVID-19 pandemic. Likert responses were coded numerically and the mean change between responses 'before' and 'during' the pandemic was calculated for the whole sample as well as by WFH categories with 95% confidence intervals.

Results

A total of 3,607 employees completed the CAPTURE survey from eight separate companies across the U.S. Seven companies were classified as industry, and one company was an academic institution. The overall mean response rate from employees within the eight

companies was 14.9%, with intra-company response rates ranging from 6.8% to 63.8%. When data were stratified by company type, results were not materially different.

Demographics

Demographic results are observed in Table 1. Most employees were from the Midwest (83.5%). Mean age was 44.7 \pm 12.1 years, with most employees classified as 'Professionals' (49.5%), followed by 'Executive, Administrator, or Senior Manager' (13.5%), and 'Clerical and Administrative Support' (11.8%). Perceived health was in 'Good', 'Very Good', or 'Excellent' condition for most (91.7%). The percentage of employees reporting that their doctor had told them they had a medical condition ranged from 2.9% for heart disease and stroke (combined) to 24.0% for mood disorder. Most employees (62.1%) reported reduced in-person contact with family who live outside the home, friends, colleagues at work, and events in the community because of COVID-19.

Socioeconomic Impact of COVID-19

Most (85.7%) employees stated they spent >90% of their time indoors when working, 90.5% stated they spent an average of 33-60 hours per week working, and 58.8% stated they currently had no face-to-face, in-person interactions with either coworkers or the public while completing their job-related duties. Few employees (0.2%) reported being furloughed or furloughed previously (or temporarily laid off). Approximately 68% believed COVID-19 had a negative impact on their work. Few (0.7%) lost health insurance or other coverage for medical care. As shown in Figure 2, with WFH percentage grouped into the four 25% categories, the distribution shifts dramatically from 'before' to 'during' the COVID-19 pandemic.

Psychosocial Outcomes and Perceptions

During the pandemic, many employees reported feeling stressed (53.1%), anxious (43.8%), and fatigued (41.1%) 'Quite a bit' or 'All the time'. The prevalence of employees agreeing they felt threatened about COVID-19 or afraid of COVID-19 were 39.4% and 60.0%, respectively, while 60.3% reported being stressed around other people because they worried they would catch COVID-19. In total, 32.4% reported being 'Moderately' or 'Very Worried' about contracting COVID-19 while at work, and 34.1% reported being 'Moderately' or 'Very Worried' about being an asymptomatic carrier.

Table 2 shows the changes in psychosocial and behavioral responses from before to during the COVID-19 pandemic, with mean change and 95% confidence intervals for each parameter. More than half of employees reported an increase in stress, anxiety, fatigue, feeling unsafe, a lack of companionship, and a feeling of being isolated from others. For the behavioral outcomes, a high percentage of employees reported a decrease in productivity and physical activity, while increases were observed for non-work screen time, sleep, and alcohol consumption.

Figure 3 shows the mean change and 95% confidence intervals for the psychosocial and behavioral responses stratified by WFH categories of >75% v. \leq 25% of worktime. As shown, mean increases were higher in the \leq 25% WFH group for stress, anxiety, fatigue, and feeling unsafe. Decreases in productivity were larger for WFH \leq 25%, while an increase in sleep was only observed in WFH >75%.

SARS-CoV-2 Prevention Behaviors at the Workplace

Employees reported 'Often' or 'Always' engaging in personal SARS-CoV-2 prevention behaviors at the workplace, as seen in Table 3. Glove wearing was an exception, with most reporting 'Never' or 'Rarely'. Table 4 shows PPE, instructions, and practices provided and promoted by the employers. Most employees reported their employer provided web training (33.4%), reading materials (24.1%), or both (25.5%).

When asked about perceptions of the importance of specific prevention behaviors and practices, most employees reported wearing a mask, handwashing, and physical distancing to be 'Very Important' (93.3%, 89.1%, and 93.5%, respectively). Disinfecting surfaces was reported as 'Very Important' by some (45.5%), while most employees reported that wearing gloves was 'Not Important' (36.2%).

COVID-19 Symptomology and Diagnosis

COVID-19 symptoms reported as lasting several hours more than usual were headaches (34.3%), followed by unusual fatigue (27.1%), malaise or general feeling of illness, discomfort or uneasiness (23.2%), and muscle aches (22.3%). In total, 13.1% of employees suspected they had a COVID-19 infection or had COVID-19 symptoms. Most reported having a negative nasal swab or spit test (52.9%) and a negative blood/antibody test (9.9%). Few had a positive nasal swab or spit test (4.0%) and positive blood/antibody test (1.0%).

Discussion

We observed large increases in stress, anxiety, fatigue, and feeling unsafe among nonhealthcare employees due to the COVID-19 pandemic. We also noted an increase in lack of

companionship, feeling left out, or isolation when completing their work-related duties, with decreased productivity and physical activity reported. These changes may have been due to quarantining and the sudden shift to WFH. Most employees were afraid of COVID-19 and stressed about acquiring the disease in general. Interestingly, however, not as many employees were worried about contracting COVID-19 at work or being an asymptomatic carrier of COVID-19 while at work, regardless of WFH status. A high percentage of employees believed wearing a mask, handwashing, and physical distancing were important in preventing the spread of COVID-19, whereas wearing gloves and disinfecting surfaces were thought to be less important. While productivity and physical activity decreased for many, non-work screen time increased. Sleep also increased in a small percentage of employees and, in particular, those engaged in >75% WFH each week, which may be due to the absence of commuting to and from the workplace. Alcohol consumption increased in a quarter of respondents, possibly related to stress.

Research has shown adverse psychosocial changes during the COVID-19 pandemic, with higher levels of anxiety, depression, PTSD, and stress observed among the general population in multiple countries.¹⁵ In the U.S., a survey conducted from March through June 2020 found that distress increased as the pandemic first emerged in the U.S., including increases in anxiety and depression.⁶⁷ Literature has suggested psychosocial support to be critical to mitigating these adverse changes, as individuals reporting having no psychosocial support were more vulnerable to mental health problems during the COVID-19 pandemic.⁶⁸ These observations align with our findings from employees across the U.S. and suggest employers might need to make concerted efforts to assist employees in dealing with mental health issues as more individuals return to the office. Notably, our observations suggest that the focus of employers may need to be most concentrated on those who have worked the least amount of time at home during COVID-19.

15

Our behavioral outcome observations were also largely consistent with previous research on the COVID-19 pandemic. Increased non-work technology usage¹⁴ and screen time⁶⁹ have been seen in previous studies. Interestingly, we saw a slight increase in hours of sleep per night among employees >75% WFH each week, but not among employees $\geq 25\%$ WFH each week. Despite the increased sleep duration observed among some, other research during the COVID-19 pandemic has suggested individuals' sleep quality has been poorer.¹⁴ Reductions in physical activity were also observed in existing research.⁶⁹ More investigation of these phenomena, as well as changes in alcohol consumption, may be warranted. We believe our ongoing follow-up CAPTURE Surveys will provide more insight.

A secondary aim of CAPTURE was to assess personal SARS-CoV-2 transmission prevention behaviors taken at the workplace to mitigate the spread of COVID-19. While wearing a mask, washing hands regularly, physically distancing from coworkers, and monitoring symptoms were reported in high percentages, wearing gloves and disinfecting surfaces were not as common. This may be explained by the changing viewpoints of SARS-CoV-2 virus spread and associated mitigation strategy guidance set forth by the CDC⁷⁰ and the World Health Organization's (WHO)⁷¹ suggesting that surface-based transmission is less common. Importantly, employees reported their companies to be highly supportive of SARS-CoV-2 prevention behavior engagement. Indeed, many companies provided COVID-19 prevention training for their employees, which may have also aided in the high percentage of prevention behaviors reported.

Study limitations should be noted. First, participants were a convenience sample. Over 200 companies were contacted, but the companies that did partake in the survey had previously worked with, or were connected to, the research institutions. This convenience sample skewed

16

the educational status of participants, with more than half of participants having a graduate degree. Second, while we asked about job status, we did not ask if employees identified as essential or non-essential workers due to the multidimensional nature of the companies. Future questionnaires should include perceptions of essential worker status or have a defined strategy to determine if employees are considered essential or non-essential workers. Finally, this was a cross-sectional analysis of a prospective survey. The questions asking about outcomes and perceptions "Before COVID-19" were therefore retrospective and subject to recall bias. However, we have future papers planned to describe prospective observations related to our ongoing follow-up CAPTURE Surveys. The survey was subjective and only asked about perceptions, feelings, and behaviors. Objective measures should be considered for future studies when feasible.

Nevertheless, the study had its strengths including: (1) a large sample size; (2) a wide range of WFH percentages; and (3) a sample of non-healthcare employees. These strengths provided unique insight into psychosocial and behavioral responses of employees working outside of the healthcare workforce during COVID-19. The increases in stress, anxiety, fatigue, and feeling unsafe due to work-related duties, as well as adverse changes in health behaviors (e.g., increased non-work screen time, decreased physical activity), suggest companies might consider how to support their employees as employees begin to return to the office in greater numbers.

References

1. University JH. Johns Hopkins Coronavirus Resource Center.

https://coronavirus.jhu.edu/map.html Accessed May 11, 2020.

- WHO. WHO director-general's opening remarks at the media briefing on COVID-19 11 March
 2020. <u>https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-</u>
 <u>the-media-briefing-on-covid-19---11-march-2020</u>.
- 3. Richardson S, Hirsch J, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA* 2020;**323**(20):2052-2059.
- He X, Lau E, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19.
 Nature Medicine 2020;**26**:672-675.
- 5. West R, Michie S, Rubin GJ, Amlot R. Applying principles of behaviour change to reduce SARS-CoV-2 transmission. *Nature Human Behavior* 2020;**4**:451-459.
- Lake MA. What we know so far: COVID-19 current clinical knowledge and research. *Clin Med* (Lond) 2020;**20**(2):124-127.
- 7. Van Bavel JJ, Baicker K, Boggio PS, et al. Using social and behavioural science to support COVID 19 pandemic response. *Nature Human Behavior* 2020;**4**:460-471.
- 8. Zhang J, Lu H, Zeng H, et al. The differential psychological distress of populations affected by the COVID-19 pandemic. *Brain, Behavior, and Immunity* In Press:DOI: 10.1016/j.bbi.2020.03.007.
- 9. Holmes E, O'Connor R, Perry V, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *The Lancet* In Press:DOI: 10.1016/S2215-0366(20)30168-1.
- 10. Dubey S, Biswas P, Ghosh R, et al. Psychosocial impact of COVID-19. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2020;**14**:779-788.

- 11. Wang C, Pan R, Wan X, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. *International Journal of Environmental Research and Public Health* 2020;**17**:doi: 10.3390/ijerph17051729.
- 12. Cao W, Fang Z, Hou G, et al. The psychological impact of the COVID-19 pandemic on college students in China. *Psychiatry Research* 2020;**287**:doi: 10.1016/j.psychres.2020.112934.
- Latkin CA, Dayton L, Moran M, Strickland JC, Collins K. Behavioral and psychosocial factors associated with COVID-19 skepticism in the United States. *Curr Psychol* 2021:1-9.
- 14. Ammar A, Trabelsi K, Brach M, et al. Effects of home confinement on mental health and lifestyle behaviours during the COVID-19 outbreak: insights from the ECLB-COVID19 multicentre study. *Biol Sport* 2021;**38**(1):9-21.
- 15. Hossain MM, Tasnim S, Sultana A, et al. Epidemiology of mental health problems in COVID-19: a review. *F1000Res* 2020;**9**:636.
- 16. Hossain MM, Sultana A, Purohit N. Mental health outcomes of quarantine and isolation for infection prevention: a systematic umbrella review of the global evidence. *Epidemiol Health* 2020;**42**:e2020038.
- Liu J, Liao X, Qian S, et al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. *Emerging Infectious Diseases* 2020:DOI: 10.3201/eid2606.200239.
- 18. Chan J-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* 2020;**395**(10223):P514-523.
- 19. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia. *New England Journal of Medicine* 2020;**382**.

- 20. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020;**395**(10223):P497-506.
- 21. Burke R, Midgley C, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19--United States, January-February 2020. *Morbidity and Mortality Weekly Report* 2020;**69**(9).
- 22. WHO. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). Geneva, Switzerland: World Health Organization, 2020.
- 23. Ong S, Tan Y, Chia P, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. *JAMA* 2020;**323**(16):1610-1612.
- 24. Ai Z, Melikov A. Airborne spread of expiratory droplet nuclei between the occupants of indoor environments: a review. *Indoor Air* 2018;**28**(4):DOI: 10.1111/ina.12465.
- 25. Dietz L, Horve P, Coil D, et al. 2019 novel coronavirus (COVID-19) pandemic: built environment considerations to reduce transmission. *mSystems* 2020;**5**:DOI: 10.1128/mSystems.00245-20.
- 26. van Doremalen N, Bushmaker T, Morris D, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *New England Journal of Medicine* 2020;**382**(16):1564-1567.
- 27. Liu Y, Ning Z, Chen Y, et al. Aerodynamic Analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* 2020:DOI: 10.1038/s41586-020-2271-3(2020).
- Schoen L. Guidance for building operations during the COVID-19 pandemic. ASHRAE Journal.
 Atlanta, GA: American Society of Heating Refrigerating and Air-Conditioning Engineers, 2020.
- 29. Otter J, Donskey C, Yezli S, et al. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. *Journal of Hospital Infection* 2016;**92**:235-250.

- 30. Bahl P, Doolan C, de Silva C, et al. Airborne or droplet precautions for health workers treating coronavirus disease 2019. *Journal of Infectious Diseases* 2020:DOI: 10.1093/infdis/jiaa189.
- 31. Vejerano E, Marr L. Physio-chemical characteristics of evaporating respiratory fluid droplets. Journal of the Royal Society Interface 2018:DOI: 10.1098/rsif.2017.0939.
- 32. Yang S, Lee G, Chen C-M, Wu C-C, Yu K-P. The size and concentration of droplets generated by coughing in human subjects. *J Aerosol Med* 2007;**20**(4):484-494.
- Fennelly K, Martyny J, Fulton K, et al. Cough-generated aerosols of mycobacterium tuberculosis:
 A new method to study infectiousness. *Am J Respir Crit Care Med* 2004;**169**(5):604-609.
- Gupta J, Lin C-H, Chen Q. Flow dynamics and characterization of a cough. *Indoor Air* 2009;19(6):517-525.
- Xie X, Li Y, Sun H, Liu L. Exhaled droplets due to talking and coughing. *J R Soc Interface*2009;6:doi: 10.1098/rsif.2009.0388.focus.
- 36. Zhu S, Kato S, Yang J-H. Study on transport characteristics of saliva droplets produced by couching in a calm indoor environment. *Building and Environment* 2006;**41**(12):1691-1702.
- 37. Louden R, Roberts R. Droplet expulsion from the respiratory tract. *American Review of Respiratory Disease* 1967;**95**(3):435-442.
- Duguid J. The size and duration of air-carriage of respiratory droplets and droplet-nuclei.
 Epidemiol Infect 1946;44(6):471-479.
- 39. Lindsley W, Pearce T, Hudnall J, et al. Quantity and size distribution of cough-generated aerosol particles produced by influenza patients during and after illness. *J Occup Environ Hyg* 2012;**9**(7):443-449.
- 40. Lindsley W, Reynolds J, Szalajda J, Noti J, Beezhold D. A cough aerosol simulator for the study of disease transmission by human cough-generated aerosols. *Aerosol Science and Technology* 2013;**47**(8):937-944.

- 41. Lindsley W, Blachere F, Beezhold D, et al. Viable influenza A virus in airborne particles expelled during coughs versus exhalations. *Influenza Other Respir Viruses* 2016;**10**(5):404-413.
- 42. Bourouiba L, Dehandschoewercker E, Bush J. Violent expiratory events: on coughing and sneezing. *Journal of Fluid Dynamics* 2014;**745**:537-563.
- Zayas G, Chiang M, Wong E, et al. Cough aerosol in healthy participants: fundamental knowledge to optimize droplet-spread infectious respiratory disease management. *BMC Pulmonary Medicine* 2012;**11**:doi: 10.1186/1471-2466-12-11.
- 44. Scharfman B, Techet A, Bush J, Bourouiba L. Visualization of sneeze ejecta: steps of fluid fragmentation leading to respiratory droplets. *Experiments in Fluids* 2016;**57**(2):24.
- 45. Han Z, Weng W, Huang Q. Characterizations of particle size distribution of the droplets exhaled by sneeze. *J R Soc Interface* 2013;**10**(88):doi: 10.1098/rsif.2013.0560.
- 46. Morawska L, Johnson G, Ristovski Z, et al. Size distribution and sites of origin of droplets expelled from the human respiratory tract during expiratory activities. *Journal of Aerosol Science* 2009;**40**(3):256-269.
- 47. Edwards D, Man J, Brand P, et al. Inhaling to mitigate exhaled bioaerosols. *PNAS*2004;**101**(50):17383-17388.
- 48. Papineni R, Rosenthal F. The size distribution of droplets in the exhaled breath of healthy human subjects. *Journal of Aerosol Medicine* 1997;**10**(2):105-116.
- 49. Fabian P, McDevitt J, DeHaan W, et al. Influenza virus in human exhaled breath: an observational study. *PLoS One* 2008;**3**(7):doi: 10.1371/journal.pone.0002691.
- 50. Asadi S, Wexler A, Cappa C, et al. Aerosol emission and superemission during human speech increase with voice loudness. *Scientific Reports* 2019;**9**(1):1-10.
- 51. Gupta J, Lin C-H, Chen Q. Characterizing exhaled airflow from breathing and talking. *Indoor Air* 2010;**20**(1):31-39.

- 52. Stadnytskyi V, Bax C, Bax A, Anfinrud P. The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. *PNAS* 2020;**117**(22):11875-11877.
- 53. Chu D, Akl E, Duda S, et al. Physical distancing, face masks, and eye protection to prevention person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and metaanalysis. *Lancet* 2020;**395**:1973-1987.
- 54. Rabenau H, Kampf G, Cinatl J, Doerr H. Efficacy of various disinfectants against SARS coronavirus. *Journal of Hospital Infection* 2005;**61**:107-111.
- 55. Sattar S, Springthorpe V, Karim Y, Loro P. Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses. *Epidem Inf* 1989;**102**:493-505.
- 56. Wood A, Payne D. The action of three antiseptics/disinfectants against enveloped and nonenveloped viruses. *Journal of Hospital Infection* 1998;**38**:283-295.
- 57. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. *Dermatology* 2006;**212**:119-123.
- 58. Omidbakhsh N, Sattar S. Broad-spectrum microbicidal activity, toxicologic assessment, and materials compatibility of a new generation of accelerated hydrogen peroxide-based environmental surface disinfectant. *Am J Infect Control* 2006;**34**:251-257.
- 59. Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus ankara (MVA). *Infect Dis Ther* 2015;**4**:491-501.
- 60. CDC. Coronavirus disease 2019: businesses & workplaces-plan, prepare, and respond. Atlanta, GA: Centers for Disease Control and Prevention, 2020.
- 61. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: Study Design, Recruitment, and Some Characteristics of the Examined Subjects. *J Clin Epidemiol* 1988;**41**(11):1105-1116.


- 62. Pereira M, Mullane S, Toledo MJ, et al. Efficacy of the 'Stand and Move at Work' multicomponent workplace intervention to reduce sedentary time and improve cardiometabolic risk: a group randomized clinical trial. *International Journal of Behavioral Nutrition and Physical Activity* 2020;**17**(133).
- 63. (NIH) NIoH. COVID-19 Questionnaire Adult Primary Version. In: (ECHO) EioCHO, ed, 2020.
- 64. Manning KJ, Steffens, D.C., Grasso, D.J., Briggs-Gowan, M.J., Ford, J.D., & Carter, A.S. The Epidemic - Pandemic Impacts Inventory Geriatric Adaptation (EPII-G). University of Connecticut School of Medicine, 2020.
- 65. Hughes ME, Waite LJ, Hawkley LC, Cacioppo JT. A Short Scale for Measuring Loneliness in Large Surveys: Results from Two Population-Based Studies. *Res Aging* 2004;**26**:655-672.
- 66. Conway LG, III, Woodard, S. R., & Zubrod, A. Social Psychological Measurements of COVID-19:
 Coronavirus Perceived Threat, Government Response, Impacts, and Experiences Questionnaires.
 <u>https://psyarxiv.com/z2x9a/</u>.
- 67. Daly M, Robinson E. Psychological distress and adaptation to the COVID-19 crisis in the United States. *J Psychiatr Res* 2021;**136**:603-609.
- 68. Lei L, Huang X, Zhang S, et al. Comparison of Prevalence and Associated Factors of Anxiety and Depression Among People Affected by versus People Unaffected by Quarantine During the COVID-19 Epidemic in Southwestern China. *Med Sci Monit* 2020;**26**:e924609.
- 69. Meyer J, McDowell C, Lansing J, et al. Changes in Physical Activity and Sedentary Behavior in Response to COVID-19 and Their Associations with Mental Health in 3052 US Adults. *Int J Environ Res Public Health* 2020;**17**(18).
- 70. Prevention CfDCa. COVID-19. <u>https://www.cdc.gov/coronavirus/2019-ncov/index.html</u> Accessed May 7, 2021.

71. (WHO) WHO. Coronavirus disease (COVID-19): How is it transmitted? World Health

Organization (WHO), 13 December 2020.

Figure 1. Flowchart of the companies who expressed interest and participation

status.



Gender	Count	%
Female/Women	2292	67.4%
Male/Men	1063	31.3%
Other/Nonbinary	33	1.0%
Age		
<35	896	26.9%
35-65	2309	71.8%
>65	125	3.8%
Hispanic or Latino/Latina/Latinx		
Yes	124	3.5%
Which of the following best describes you?		
Asian, Black or African-American	217	6.4%
Other	216	6.4%
White	2924	86.0%
Current marital status		
Married or partnered	2469	72.6%
Highest level of schooling completed		
Less than Bachelor's degree	364	10.7%
Bachelor's degree	1260	37.1%
Master's, Professional, or Doctoral degree	1762	51.8%

Table 1. Demographic results of the Baseline CAPTURE Survey.^a

^a Prefer not to answer were not included in the above table and were less than 2% of the responses.

		Decrea	sed	No Ch	nange	Increa	ased	Mean	95%
		(Count,	%)	(Coun	t, %)	(Coun	t, %)	Change	Confidence
									Intervals
	Stress ^a	336	10.0%	1217	36.1%	1821	54.0%	0.56	0.53 - 0.60
	Anxiety ^a	245	7.3%	1192	35.4%	1934	57.4%	0.70	0.67 – 0.73
Denshaardal	Fatigue ^a	389	11.5%	1243	36.8%	1742	51.6%	0.58	0.54 - 0.61
Psychosocial Responses	Feeling unsafe ^a	214	6.4%	1455	43.2%	1697	50.4%	0.74	0.70 - 0.78
	A lack of companionship ^c	155	4.6%	1179	34.9%	2040	60.5%	0.76	0.73 – 0.79
	A feeling of being left out ^c	247	7.3%	1716	50.9%	1408	41.8%	0.43	0.40 - 0.46
	A feeling of being isolated from others ^e	119	3.5%	918	27.2%	2338	69.3%	0.94	0.91 - 0.97
	Productivity ^a	1454	42.9%	1467	43.3%	467	13.8%	-0.51	-0.550.47
Behavioral Responses	Physical Activity ^a	1398	41.1%	1256	36.9%	750	22.0%	-0.29	-0.330.25
	Non-Work Screen Time ^b	92	2.7%	1583	46.6%	1725	50.7%	0.56	0.54 - 0.59
	Sleep ^a	545	16.0%	1778	52.2%	1085	31.8%	0.21	0.18 - 0.24
	Alcohol Consumption ^d	338	10.0%	2193	64.9%	848	25.1%	0.22	0.19 - 0.25

Table 2. Psychosocial & Behavioral Changes from Before to During the COVID-19 Pandemic

^aQuestions were asked on a 5-point Likert scale ^bQuestions were asked on a 4-point Likert scale

^cQuestions were asked on a 3-point Likert scale ^dQuestions were asked on a 9-point Likert scale




Figure 2. WFH Categories Before & During the COVID-19 Pandemic

Figure 3. Psychosocial & Behavioral Responses (Mean, 95% Confidence Intervals) from Before to During the

COVID-19 Pandemic Stratified by WFH Status ($\leq 25\%$ *WFH vs* >75% *WFH*)




Table 3. Personal COVID-19 Prevention Behaviors During COVID-19 Pandemic

_

	Never/Rarely (<i>Count</i> , %)		Sometimes (Count, %)		Often/Always	
					(Coun	t, %)
Worn a mask of any type	18	0.9%	18	0.9%	1982	98.2%
Worn gloves	1225	64.1%	353	18.5%	332	17.4%
Washed my hands regularly	21	1.0%	66	3.3%	1932	95.7%
Physically distanced from coworkers or	27	1.4%	100	5.0%	1870	93.6%
public						
Disinfected surfaces	334	17.5%	371	19.4%	1209	63.2%
Monitored symptoms prior to work	293	14.9%	203	10.3%	1474	74.8%

Table 4. Workplace Culture, Practices	& PPE Provided &	Promoted by Companies ^a
---------------------------------------	------------------	------------------------------------

		Never/Rarely (<i>Count</i> , %)		Sometimes (<i>Count</i> , %)		Often/Always (<i>Count</i> , %)	
	N95 masks	1750	50.4%	152	4.4%	279	8.0%
	Surgical masks	1230	35.4%	198	5.7%	855	24.6%
	Cloth masks	741	21.2%	593	16.9%	1287	36.8%
PPE &	Gloves	1077	30.9%	240	6.9%	959	27.5%
Instructions	Hand sanitizer	270	7.7%	174	5.0%	2265	64.8%
Provided	Hand washing instructions	130	3.7%	163	4.7%	2512	71.8%
	Physical distancing instructions	77	2.2%	160	4.6%	2652	75.8%
	Cleaning/disinfecting products for surfaces	265	7.6%	246	7.0%	2068	59.1%
	Tools to monitor symptoms prior to work	1286	36.8%	136	3.9%	936	26.8%
PPE & Practices	N95 masks	1425	41.1%	353	10.2%	761	21.9%
Promoted	Surgical masks	831	23.9%	281	8.1%	1589	45.7%

Cloth masks	136	3.9%	182	5.2%	2805	80.2%
Gloves	1276	36.7%	497	14.3%	932	26.8%
Hand sanitizer	95	2.7%	208	6.0%	2863	81.9%
Hand washing	38	1.1%	90	2.6%	3105	88.9%
Physical distancing	27	0.8%	80	2.3%	3137	89.7%
Surface cleaning/disinfecting	184	5.3%	337	9.6%	2529	72.4%
Monitoring of symptoms prior to work	241	6.9%	243	7.0%	2549	73.0%

^a Row totals don't add to 100% because of a lack of applicability to working at home

_